HTS for PK/DM studies in the discovery stage(SYMPOSIUM 2 : PHARMACOKINETIC & TOXICOLOGIC RESEARCH STRATEGIES IN THE EARLY STAGES OF DRUG DISCOVERY)

スポンサーリンク

概要

• 論文の詳細を見る

• Kennedy reviewed that 39% of the halts in development occurred for problems related to PK/DM, whereas 30% were due to a lack of clinical efficacy and 21% were caused by safety issues (includes animal toxicity). However, the position of PK/DM and safety issues have been completely reversed by the HTS that now routinely take place in the various stages of discovery. The future success of drug development in large part depends on developing screening systems which more accurately predict the safety of compounds in the Discovery stage and on clarifying Structure-Safety Relationships through the use of HTS.

• 日本トキシコロジー学会の論文

著者

• Shimada Kaoru

  Pharmacokinetics Dynamics & Metabolism Pfizer Global Research & Development Japan

関連論文

• HTS for PK/DM studies in the discovery stage(SYMPOSIUM 2 : PHARMACOKINETIC & TOXICOLOGIC RESEARCH STRATEGIES IN THE EARLY STAGES OF DRUG DISCOVERY)

スポンサーリンク